Perficient: Drug Development

FEBRUARY 22, 2024

The Folly of Following Trends Trends are, by definition, people following a current style or popular approach. At that time, their industry was driven by government regulations and tariffs. Not once have I had a group who wasn’t able to produce an intriguing idea within five to ten minutes based on a random word. Great ideas abound!

Marketing 116

Marketing Production Government Regulations 116

Drug Target Review

OCTOBER 31, 2023

Regulatory affairs workers get to tell a story about a drug to the regulators and – keeping the end in mind, which is the drug label or prescribing information – is a good way to communicate with regulators. Every drug has a story: an end game. By definition, this is the cutting edge, and we are in it.

Cell Biology 107

Cell Biology Pharmaceuticals Science Disease 107

Perficient: Drug Development

JANUARY 24, 2024

Before I begin, I just want to caveat everything with the fact that HIPAA is a complex regulation open to interpretation, and in the end your legal and compliance teams need to be comfortable with how you handle data and the risk associated with those methods. The other part of the definition is what constitutes “health information.”

Licensing 96

Licensing Licensing Production Regulations 96

Perficient: Drug Development

AUGUST 21, 2024

Understanding Adaptive and Assistive Technologies Adaptive Technologies: Definition: Adaptive technologies are specialized tools and modifications designed to assist individuals with disabilities in performing tasks that might otherwise be challenging or impossible. These technologies often support independence and improve quality of life.

Regulations 52

Regulations Compliance Treatment 52

The Premier Consulting Blog

OCTOBER 11, 2022

Key Takeaway RWD and RWE play an important role in rare diseases, where capturing relevant data to support drug development is challenging. To learn more about using RWD and RWE in rare disease programs, read our guide on Using Real-World Data and Real-World Evidence to Support Rare Disease Programs.

Disease 52

Disease FDA FDA Approval Treatment 52

Agency IQ

JULY 12, 2024

BY LAURA DIANGELO, MPH | JUL 10, 2024 3:47 PM CDT Regulatory background: The FDA is responsible for overseeing information about regulated products. The FDA is responsible for ensuring that medical products are adequately labeled in accordance with federal regulations, including the product’s “intended use” and relevant safety information.

FDA 40

FDA Regulations Production Science 40

FDA Law Blog: Drug Discovery

OCTOBER 2, 2023

Two weeks ago, FDA published a draft of its latest drug development guidance explaining how drug and biological product developers can use this pathway to meet the statutory standard for efficacy. The guidance’s second warning reminds drug developers that FDA regulations (i.e.,

FDA 64

FDA Drug Development Disease Trials 64

Perficient: Drug Development

MARCH 22, 2024

Even the definition of “good” is harder to define with unstructured data than structured data. Conclusion Enterprise data, particular in regulated industries, rely on robust, effective and ubiquitous quality pipelines. Working with unstructured data, particularly at scale, can be difficult. An elusive goal, at best.

International 52

International Regulations Research 52

Agency IQ

JUNE 26, 2023

Today, the FDA unveiled a contract notice that explains the process for how it will develop that report, obtain public input, and deliver the report’s final recommendations. a disease or condition is defined as rare by the Orphan Drug Act (ODA) if it affects fewer than 200,000 people. regulators. In the U.S., Recently, U.S.

FDA 40

FDA Disease Regulations Production 40

Agency IQ

NOVEMBER 3, 2023

In particular – potential issues with applying the policy to practice, the role of different stakeholders and the new proposed definitions. IVDs are regulated as medical devices in the U.S., However, this definition presents many questions. but since the 1970s, the FDA has expressed “enforcement discretion” (i.e.,

FDA 40

FDA Laboratories Regulations Production 40

The Premier Consulting Blog

MARCH 13, 2023

In addition to describing the intended purpose of the procedure, the ATP outlines anticipated performance criteria and Critical Quality Attributes (CQAs), which facilitate technology selection, procedure design and development, performance monitoring, and continual improvement.

International 52

International Production Regulations Drugs 52

FDA Law Blog: Drug Discovery

NOVEMBER 2, 2023

The standards would, as stated previously, be voluntary, unless mandated by statute or regulation, and they cannot conflict with existing law or regulation. Consensus does not require unanimity, but a general agreement. Existing published VCS may be identified internally by FDA or externally by stakeholders.

Therapies 59

Therapies FDA Production Regulations 59

Perficient: Drug Development

NOVEMBER 1, 2024

AI, by definition, involves the development of computer systems that can perform tasks typically requiring human intelligence. Protecting this data from breaches and ensuring compliance with regulations like HIPAA is essential to maintain patient trust and confidentiality.

Treatment 52

Treatment Regulations Compliance Disease 52

Agency IQ

JUNE 9, 2023

What will the orphan drug market exclusivity haircut mean for industry? Just over a month ago, the European Commission released its proposal for the new pharmaceutical directive and regulation. Other orphan drugs, which, by definition, address an unmet medical need, “only” receive 9 years of market exclusivity.

Marketing 40

Marketing Regulations Biosimilars Drugs 40

Perficient: Drug Development

JULY 5, 2024

Security and Compliance: ChatBOTs prioritize security and compliance by implementing measures such as encryption, access controls, and adherence to data protection regulations to safeguard user information and ensure privacy. Let’s add a pipeline, Definition will be Pipeline Script. You must add this inside job like the below image.

Compliance 52

Compliance Regulations Production 52

Agency IQ

MAY 31, 2024

The legislation further explained that for a certain method to qualify as a “platform technology,” it must demonstrate “reasonable likelihood to bring significant efficiencies to drug development and review processes.” How can sponsors “prove” that these three criteria are met?

Science 40

Science FDA Production Licensing 40

Agency IQ

JANUARY 19, 2024

The work could represent early steps toward modernizing one part of FDA’s regulation of this complicated product class. BY AMANDA CONTI | JAN 16, 2024 7:43 PM CST Regulatory background: complex generics Unlike new drug products, generic drugs do not require extensive clinical evidence to demonstrate safety or efficacy.

FDA 40

FDA Research Production Regulations 40

FDA Law Blog: Drug Discovery

DECEMBER 6, 2024

As much of the content of this draft guidance for cellular and gene therapy (CGT) products is articulated elsewhere, this document serves as a one-stop shop or Cliffs Notes for the numerous guidance documents now covering CGT product development.

Therapies 59

Therapies FDA Production Disease 59

Perficient: Drug Development

NOVEMBER 22, 2023

Compliance and Regulation: Azure AD B2C provides compliance with industry regulations such as GDPR and HIPAA, as well as support for authentication standards like OpenID Connect and OAuth 2.0. This makes it easier for businesses to comply with regulatory requirements and ensure the security of user data.

Compliance 52

Compliance Regulations Licensing Licensing 52

Perficient: Drug Development

OCTOBER 7, 2024

However, the new lengthy regulation raised many questions by the industry, and Perficient’s Financial Services Risk and Regulatory consultants have been researching answers and questioning regulators to provide in order to provide our current and future clients the answers to the following questions that have been raised.

Compliance 52

Compliance Regulations Research 52

Agency IQ

SEPTEMBER 1, 2023

For example, in September 2022 the FDA finalized a guidance document on how sponsors of drug product submissions could effectively flag RWE for regulators. Overall, the FDA urged developers to engage with the agency early – including through a Type C meeting – to go over their planned protocol and statistical analysis plan (SAP).

FDA 40

FDA Science Regulations Production 40

DrugBank

JUNE 27, 2023

The general notion is that patients should be viewed individually, rather than strictly as members of some larger general population, and that their specific genetic background, environment, and lifestyle choices should be considered throughout drug development to the point of treatment and continuing patient care.

Disease 87

Disease Treatment Drugs Clinical Trials 87

The Premier Consulting Blog

OCTOBER 26, 2022

During the development cycle of a regulated therapeutic, the transfer of the manufacturing process is inevitable. The process will be transferred from the development lab to a pilot or small-scale manufacturing facility and, if the program is successful, to a facility for commercial manufacturing.

Production 40

Production Assay Development Clinical Supply Engineering 40

Agency IQ

JULY 22, 2024

If a drug was previously approved for cancer, but is now approved for a cardiology condition, it would not be considered novel. While the definition of NME has changed over the years, it can sometimes include a combination product consisting of at least one drug that has previously been approved.

Clinical Trials 52

Clinical Trials Trials Science FDA 52

Agency IQ

JUNE 26, 2023

Because CDx are diagnostic devices, they are not considered part of a combination product but are regulated separately as medical devices. But not all tests and diagnostics used with a drug product are actually CDx.

FDA 40

FDA Laboratories Clinical Trials Science 40

Agency IQ

SEPTEMBER 22, 2023

In 1972, when regulatory authority for biologic products was transferred from the National Institutes of Health (NIH) to the FDA, the agency extended the two-study framework to biologic regulation as well. The Heckler case helped to refine the definition of “substantial evidence” in two important ways.

FDA 40

FDA Science Trials Clinical Trials 40

Agency IQ

DECEMBER 1, 2023

The FDA also implemented new flexibilities for certain regulated products and processes, typically via enforcement discretion. As before, the guidance provides recommendations on drug development for COVID-19 across five domains: population, trial design, efficacy endpoints, safety considerations and statistical considerations.

FDA 40

FDA Clinical Trials Vaccine Trials 40

Agency IQ

JUNE 9, 2023

BY RACHEL COE, MSC JUN 6, 2023 5:00 PM CDT What are nonclinical studies and when are they conducted in drug development? It also contains a definition of the term immunotoxicity— the unintended immunosuppression or stimulation (including hypersensitivity) —which was notably absent from the draft.

FDA 40

FDA Small Molecule Science Immune Response 40

Agency IQ

FEBRUARY 2, 2024

The EMA started providing guidance on the clinical development of anticancer therapeutics in 1996. The document has been updated over time to implement advances in understanding cancer and drug development. In 2005, the guidance was updated to include non-cytotoxic drugs were gaining in importance.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40

Agency IQ

JUNE 21, 2024

Modeled on the Operation Warp Speed vaccine development communications approach, the pilot aims to test out a rapid communications approach for accelerating rare disease drug development. The idea is that the development challenges faced for a disease which only affects a few hundred patients in the U.S.

Disease 40

Disease Science FDA Production 40

Agency IQ

DECEMBER 11, 2023

Previously, burdensome side effects may have been written off as a necessary part of treatment and benefits measured in additional weeks or months of survival time; today, though, patients, clinicians, and regulators expect more.

FDA 40

FDA Science Clinical Trials Trials 40

Agency IQ

APRIL 12, 2024

The regulations also explain that this trait can be demonstrated via appropriate laboratory tests or adequately controlled clinical data. The first (pages 1-5) explains what regenerative medicine products are, provides an overview of what “risk management” means, and cites the requirements that drug developers must satisfy per the U.S.

Production 40

Production FDA Therapies Biochemical Assays 40

Agency IQ

NOVEMBER 10, 2023

The Artificial Intelligence Executive Order: What does it mean for FDA and its regulated industries? Last week, President Biden signed a new executive order on a federal approach to artificial intelligence (AI) regulation. Quick recap: What an EO is, and what it’s not.

Regulations 40

Regulations FDA Government Drug Development 40

Conversations in Drug Development Trends

MAY 1, 2024

Early and Ongoing Engagement Will Save Effort During Your Oncology Clinical Trial Early and ongoing engagement with regulatory agencies is invaluable; initiating dialogue early in the development process facilitates a clearer understanding of regulatory requirements and expectations and builds a relationship with regulators.

Clinical Research 69

Clinical Research Trials Clinical Trials Research 69

Agency IQ

DECEMBER 1, 2023

What We Expect the FDA to do in December 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more.

FDA 40

FDA Science Regulations Production 40

Agency IQ

FEBRUARY 12, 2024

Under the FDA’s Good Guidance Practices regulation at 21 CFR 10.115 , the agency is required to annually publish “a list of possible topics for future guidance document development or revision during the next year.” Our review found that CDER is planning several notable new guidances, including one on artificial intelligence.

Biosimilars 40

Biosimilars Science Clinical Pharmacology FDA 40

Agency IQ

AUGUST 2, 2024

Department of Commerce, was directed to take the lead on much of the cross-Department work under the AI EO in 2023, including framing underlying frameworks/guidance on developing, using and overseeing AI that can be used across the federal government. The interpretation of CDS has, notably, been a point of debate in the last few years.

FDA 40

FDA Laboratories Pharmacy Government 40